Enanta to Present Phase 2b RSV Trial Showing One-Week Symptom Reduction and Resistance Barrier
Enanta will present two oral sessions on Zelicapavir at ESCMID Global 2026 in Munich, detailing Phase 2b adult trial results showing a one-week faster RSV symptom resolution, reduced hospitalizations and strong exposure multiples over EC90. A second session will disclose pediatric Phase 2 findings confirming a robust antiviral resistance barrier.
1. ESCMID Global 2026 Presentations
Enanta will present two oral sessions on April 18, 2026 at ESCMID Global 2026 in Munich: one in Hall A1-3 focusing on high-risk adult Phase 2b RSVHR data and an ePoster session in Arena 2 highlighting pediatric resistance findings.
2. Phase 2b Adult RSV Trial Results
The Phase 2b study in high-risk adults demonstrated roughly one-week faster complete symptom resolution, a lower hospitalization rate, and strong exposure multiples over the EC 90 threshold.
3. Pediatric Phase 2 Resistance Data
Pediatric Phase 2 data confirmed Zelicapavir’s high clinical and functional barrier against antiviral resistance, underscoring durable efficacy potential across age groups.
4. Enanta’s Pipeline and Funding
Enanta is advancing Zelicapavir as an oral, once-daily N-protein inhibitor for RSV while its royalty revenue from HCV protease inhibitor glecaprevir supports ongoing R&D efforts.